 The purpose of this study is to evaluate the safety of administration and effects of valproic acid on clusterin expression in cognitively-intact, healthy, elderly subjects. Clusterin mutations have recently been identified as a risk factor for the development of Alzheimers Disease and changes in clusterin expression are seen in the elderly who develop Alzheimers disease irrespective of whether they carry these genetic mutations or not. Valproic acid may prevent or reverse these changes. 